The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
Open accessAbstract
High-throughput and virtual screening are widely used to discover novel leads for drug design. On examination, many screening hits appear non-drug-like: they act noncompetitively, show little relationship between structure and activity, and have poor selectivity. Attempts to develop these peculiar molecules into viable leads are often futile, and much time can be wasted on the characterization of these "phony" hits. Despite their common occurrence, the mechanism of action of these promiscuous molecules remains unknown. To investigate this problem, 45 diverse screening hits were studied. Fifteen of these were previously reported as inhibitors of various receptors, including beta-lactamase, malarial protease, dihydrofolate reductase, HIV Tar RNA, thymidylate synthase, kinesin, insulin receptor, tyrosine kinases, farnesyltransferase, gyrase, prions, triosephosphate isomerase, nitric oxide synthase, phosphoinositide 3-kinase, and integrase; 30 were from an in-house screening library of a major pharmaceutical company. In addition to their original targets, 35 of these 45 compounds were shown to inhibit several unrelated model enzymes. These 35 screening hits included compounds, such as fullerenes, dyes, and quercetin, that have repeatedly shown activity against diverse targets. When tested against the model enzymes, the compounds showed time-dependent but reversible inhibition that was dramatically attenuated by albumin, guanidinium, or urea. Surprisingly, increasing the concentration of the model enzymes 10-fold largely eliminated inhibition, despite a 1000-fold excess of inhibitor; a well-behaved competitive inhibitor did not show this behavior. One model to explain these observations was that the active form of the promiscuous inhibitors was an aggregate of many individual molecules. To test this hypothesis, light scattering and electron microscopy experiments were performed. The nonspecific inhibitors were observed to form particles of 30-400 nm diameter by both techniques. In control experiments, a well-behaved competitive inhibitor and an inactive dye-like molecule were not observed to form aggregates. Consistent with the hypothesis that the aggregates are the inhibitory species, the particle size and IC(50) values of the promiscuous inhibitors varied monotonically with ionic strength; a competitive inhibitor was unaffected by changes in ionic strength. Unexpectedly, aggregate formation appears to explain the activity of many nonspecific inhibitors and may account for the activity of many promiscuous screening hits. Molecules acting via this mechanism may be widespread in drug discovery screening databases. Recognition of these compounds may improve screening results in many areas of pharmaceutical interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
The Hydrophobic Effect: Formation of Micelles and Biological Membranes
Tanford, C. (1991) · Medical Entomology and Zoology · Cited by 3,327
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Simple Selection Criteria for Drug-like Chemical Matter
Muegge, I., Heald, S. L., & Brittelli, D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015507e · Cited by 1,315
Walters, W. P., Stahl, M. T., & Murcko, M. A. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01163-x · Cited by 991
Structure-Based Strategies for Drug Design and Discovery
Kuntz, I. D. (1992) · Science · doi:10.1126/science.257.5073.1078 · Cited by 989
Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., & Tang, C. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980123i · Cited by 489
Boehm, H.-J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H., Luebbers, T., Meunier-Keller, N., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000017s · Cited by 375
Reactive compounds and in vitro false positives in HTS
Rishton, G. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01083-0 · Cited by 351
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
Horton, D. A., Bourne, G. T., & Smythe, M. L. (2003) · Chemical Reviews · doi:10.1021/cr020033s · Cited by 3,013
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
Du, X., Zhou, J., Shi, J., & Xu, B. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00299 · Cited by 1,861
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Self-citationThe role of natural product chemistry in drug discovery
Butler, M. S. (2004) · Journal of Natural Products · doi:10.1021/np040106y · Cited by 1,381
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Ultra-large library docking for discovering new chemotypes
Lyu, J., Wang, S., Balius, T. E., Singh, I., Levit, A., Moroz, Y. S., O’Meara, M. J., Che, T., Algaa, E., Tolmachova, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0917-9 · Cited by 998
Self-citationTwenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Integration of virtual and high-throughput screening
Bajorath, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd941 · Cited by 930
Protein tyrosine phosphatase 1B inhibitors for diabetes
Johnson, T. O., Ermolieff, J., & Jirousek, M. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd895 · Cited by 653
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Lepourcelet, M., Chen, Y.-N. P., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W., & Shivdasani, R. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00334-9 · Cited by 653
Prediction of Protein−Ligand Interactions. Docking and Scoring: Successes and Gaps
Leach, A. R., Shoichet, B. K., & Peishoff, C. E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060999m · Cited by 646
Self-citationErlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
A Specific Mechanism of Nonspecific Inhibition
McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030266r · Cited by 598
Self-citationA practical guide to large-scale docking
Bender, B. J., Gahbauer, S., Luttens, A., Lyu, J., Webb, C. M., Stein, R. M., Fink, E. A., Balius, T. E., Carlsson, J., Irwin, J. J., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00597-z · Cited by 546
Self-citationPursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
Lead discovery using molecular docking
Shoichet, B. K., McGovern, S. L., Wei, B., & Irwin, J. J. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00339-3 · Cited by 501
Self-citationIdentification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs
Seidler, J., McGovern, S. L., Doman, T. N., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030191r · Cited by 476
Self-citationAnthraquinones As Pharmacological Tools and Drugs
Malik, E. M., & Müller, C. E. (2016) · Medicinal Research Reviews · doi:10.1002/med.21391 · Cited by 448
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
A detergent-based assay for the detection of promiscuous inhibitors
Feng, B. Y., & Shoichet, B. K. (2006) · Nature Protocols · doi:10.1038/nprot.2006.77 · Cited by 429
Self-citationAn Aggregation Advisor for Ligand Discovery
Irwin, J. J., Duan, D., Torosyan, H., Doak, A. K., Ziebart, K. T., Sterling, T., Tumanian, G., & Shoichet, B. K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01105 · Cited by 418
Self-citationHigh throughput solubility measurement in drug discovery and development
Alsenz, J., & Kansy, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.007 · Cited by 412
Chemical substructures that enrich for biological activity
Klekota, J., & Roth, F. P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn479 · Cited by 392
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Inhibition of 2-oxoglutarate dependent oxygenases
Rose, N. R., McDonough, M. A., King, O. N. F., Kawamura, A., & Schofield, C. J. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00203h · Cited by 390
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Nonleadlikeness and leadlikeness in biochemical screening
Rishton, G. M. (2003) · Drug Discovery Today · doi:10.1016/s1359644602025722 · Cited by 381
Daughton, C. G. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.5947 · Cited by 377
In silico pharmacology for drug discovery: applications to targets and beyond
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707306 · Cited by 365
A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library
Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., & Austin, C. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061317y · Cited by 358
Self-citationOn the Promise of Photopharmacology Using Photoswitches: A Medicinal Chemist’s Perspective
Fuchter, M. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00629 · Cited by 343
Rules for Identifying Potentially Reactive or Promiscuous Compounds
Bruns, R. F., & Watson, I. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301008n · Cited by 338
High-throughput assays for promiscuous inhibitors
Feng, B. Y., Shelat, A., Doman, T. N., Guy, R. K., & Shoichet, B. K. (2005) · Nature Chemical Biology · doi:10.1038/nchembio718 · Cited by 336
Self-citationSearching for new allosteric sites in enzymes
Hardy, J. A., & Wells, J. A. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.10.009 · Cited by 329
Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
Chou, T.-F., Brown, S. J., Minond, D., Nordin, B. E., Li, K., Jones, A. C., Chase, P., Porubsky, P. R., Stoltz, B. M., Schoenen, F. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015312108 · Cited by 324
Lagorce, D., Bouslama, L., Becot, J., Miteva, M. A., & Villoutreix, B. O. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx491 · Cited by 317
Combs, A. P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901090b · Cited by 317
Kristjánsdóttir, K., & Rudolph, J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.07.007 · Cited by 313
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
Interpreting steep dose-response curves in early inhibitor discovery.
Shoichet, B. K. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061103g · Cited by 304
Self-citationInhibitors of Protein Methyltransferases and Demethylases
Kaniskan, H. Ü., Martini, M. L., & Jin, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 297
Structure-based drug screening for G-protein-coupled receptors
Shoichet, B. K., & Kobilka, B. K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.007 · Cited by 294
Self-citationMendgen, T., Steuer, C., & Klein, C. D. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201243p · Cited by 290
Profiling drug-like properties in discovery research
Di, L., & Kerns, E. H. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00055-3 · Cited by 278
Docking Screens for Novel Ligands Conferring New Biology: Miniperspective
Irwin, J. J., & Shoichet, B. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02008 · Cited by 277
Self-citationRishton, G. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.007 · Cited by 276
Screening in a spirit haunted world
Shoichet, B. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.014 · Cited by 276
Self-citationFAF-Drugs3: a web server for compound property calculation and chemical library design
Lagorce, D., Sperandio, O., Baell, J. B., Miteva, M. A., & Villoutreix, B. O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv353 · Cited by 272
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 269
The Light and Dark Sides of Virtual Screening: What Is There to Know?
Gimeno, A., Ojeda-Montes, M. J., Tomás-Hernández, S., Cereto-Massagué, A., Beltrán-Debón, R., Mulero, M., Pujadas, G., & Garcia-Vallvé, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061375 · Cited by 267
Protein Tyrosine Phosphatases as Drug Targets: Strategies and Challenges of Inhibitor Development
Barr, A. J. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.241 · Cited by 266
FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects
Lagorce, D., Sperandio, O., Galons, H., Miteva, M. A., & Villoutreix, B. O. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-396 · Cited by 263
Small-molecule aggregates inhibit amyloid polymerization
Feng, B. Y., Toyama, B. H., Wille, H., Colby, D. W., Collins, S. R., May, B. C. H., Prusiner, S. B., Weissman, J., & Shoichet, B. K. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.65 · Cited by 260
Self-citationIntroduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
He, X., Alian, A., Stroud, R., & Ortiz de Montellano, P. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060715y · Cited by 257
Hit discovery and hit-to-lead approaches
Keserű, G. M., & Makara, G. M. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.016 · Cited by 256
On Dihydroorotate Dehydrogenases and Their Inhibitors and Uses
Munier-Lehmann, H., Vidalain, P.-O., Tangy, F., & Janin, Y. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301848w · Cited by 209
Wang, Q., Liberti, M. V., Liu, P., Deng, X., Liu, Y., Locasale, J. W., & Lai, L. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.11.013 · Cited by 147
Modulatory profiling identifies mechanisms of small molecule-induced cell death
Wolpaw, A. J., Shimada, K., Skouta, R., Welsch, M. E., Akavia, U. D., Pe'er, D., Shaik, F., Bulinski, J. C., & Stockwell, B. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106149108 · Cited by 133
Ungermannova, D., Lee, J., Zhang, G., Dallmann, H. G., McHenry, C. S., & Liu, X. (2013) · SLAS Discovery · doi:10.1177/1087057113485789 · Cited by 70
Identification of Antifungal H + -ATPase Inhibitors with Effect on Plasma Membrane Potential
Kjellerup, L., Gordon, S., Cohrt, K. O., Brown, W. D., Fuglsang, A. T., & Winther, A.-M. L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00032-17 · Cited by 50
Potential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors
Ahmad, S., Hughes, M. A., Yeh, L.-A., & Scott, J. E. (2012) · SLAS Discovery · doi:10.1177/1087057112444927 · Cited by 44
A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors
Ahmad, S., Hughes, M. A., Lane, K. T., Redinbo, M. R., Yeh, L.-A., & Scott, J. E. (2011) · Current Chemical Genomics · doi:10.2174/1875397301105010013 · Cited by 29
Peptidomimetics That Inhibit and Partially Reverse the Aggregation of Aβ1–42
Stark, T., Lieblein, T., Pohland, M., Kalden, E., Freund, P., Zangl, R., Grewal, R., Heilemann, M., Eckert, G. P., Morgner, N., et al. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00223 · Cited by 17
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-03-09
- Volume
- 45
- Issue
- 8
- Pages
- 1712-1722
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2127287358
- Cited by
- 1,042
- References
- 31
- FWCI
- 53.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.